key: cord-0953459-9yf0rsi2 authors: Yahav, Dafna; Yelin, Dana; Eckerle, Isabella; Eberhardt, Christiane S.; Wang, Jianwei; Cao, Bin; Kaiser, Laurent title: Definitions for COVID-19 reinfection, relapse and PCR re-positivity date: 2020-12-05 journal: Clin Microbiol Infect DOI: 10.1016/j.cmi.2020.11.028 sha: bf0aded0b14e2f3f9b4efadfe7b561a77d97b5e2 doc_id: 953459 cord_uid: 9yf0rsi2 nan By the beginning of November 2020, almost 50 million cases of Coronavirus disease (COVID- 19) were reported worldwide, with over 35 million people defined as recovering from the disease. [1] According to the Centers for Disease Control and Prevention (CDC), updated on September 10 th , there were no confirmed reports to date of a person being reinfected with SARS-CoV-2 within 3 months of the initial infection. [2] In the absence of solid human data, Rhesus monkeys were challenged 28 days after first SARS-CoV-2 infection with same virus strain and did not establish reinfection [3] However on 21-Sep-2020 the European CDC (ECDC) issued a report addressing SARS-CoV-2 reinfection, citing several case studies and calling for a case definition. [4] Defining reinfection, relapsed infection and recurrence of positive (re-positive) nucleic acid detection might have clinical and epidemiological implications for treatment and infection control measures, respectively. In this commentary, we aimed to provide such definitions, including a microbiologically confirmed definition of reinfection, as well as clinical and epidemiological ones. Reinfections are observed with many respiratory viruses, including human coronaviruses. Reinfections with respiratory viruses may be due to weak or waning initial immune response (e.g., RSV), reinfection with another genotype/species (e.g., rhinoviruses), or the high variability of the viruses (e.g., influenza). Following the SARS-CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV) epidemics, specific antibodies were detected in survivors up to 24 and 34 months, respectively. The negligible risk of a second exposure to these viruses has not allowed for a clinical determination as to the immunity against reinfection. [5, 6] For endemic coronaviruses, immunity was shown to be temporary, lasting from several months to a few years, and reinfection has been reported after experimental and natural infection. [7] It is assumed that the immune response following a natural viral infection is incomplete and reinfections are possible. [8] Currently tested COVID-19 vaccine platforms such as RNA and viral vector vaccines are designed to elicit antibody and T cell responses, whereas subunit vaccines are more restricted to antibody responses, precluding the effect of active effector T cells and memory T cells. However, it is one of the subunit vaccine candidates that shows so far the highest neutralizing antibody titers and it is still unclear if a future COVID-19 vaccine will provide sustained and sterilizing immunity. SARS-CoV-2 PCR re-positivity and COVID-19 relapse within 90 after symptom onset Several publications have described cases of re-positive SARS-CoV-2 PCR following negative tests and clinical convalescence, or recurrent symptoms, compatible with COVID-19, along with a positive RT-PCR, in recovering patients. These cases were described in a timeframe of up to 90 days from acute illness, and may represent persistent/fluctuant viral shedding with persistent or recurring clinical illness, rather than true reinfection. Other viral infections or bacterial/fungal superinfections may also explain a coinciding symptomatic episode in presence of remnant SARS-CoV-2 RNA in some of these occurrences. [9] In addition, weakly re-positive PCR (Ct values J o u r n a l P r e -p r o o f > 35) results probably do not reflect true active infection, but rather non-replicating virus. [10] The clinical course of illness among hospitalized COVID-19 patients might be prolonged in patients with severe and critical disease. The median hospitalization duration in a large series from China was reportedly 22 days among survivors, with viral shedding for a median of 20 days and as long as 37 days. [11] In other reports, viral shedding from upper respiratory specimens has been detected up to 12 weeks. According to CDC, positive PCR during a 90-day timeframe probably represents prolonged shedding rather than reinfection. However, replication-competent virus has only rarely been detected up to 10-20 days, and even then mostly in cases of severe COVID-19, although even longer times have been reported for patients in an immunocompromised state. [2] In addition to prolonged shedding, re-positive PCR tests have been described in 14% of discharged patients. [12] An investigation of 285 re-positive cases by the Korean CDC (KCDC) demonstrated neutralizing antibodies in all patients, negative cultures in all 108 tested, and cycle threshold (Ct) values above 30 in 68 (89.5%) of 76 tests. [13] . Careful analysis of viral load is essential to interpret all these studies and for comparison between results should be expressed in standardized copies numbers not Ct values. In August 2020, To et al. described an asymptomatic patient from Hong-Kong with a positive SARS-CoV-2 PCR from a sample collected 142 days after a first symptomatic COVID-19 episode. The second sample was collected as airport screening following travel to Europe. Whole genome sequencing showed a virus from a different clade/lineage. Seroconversion of SARS-CoV-2 IgG occurred only during the second episode. This case was summarized by the authors as reinfection of SARS-CoV-2. [14] Two other cases of possible reinfection were reported from USA. In these cases, a second more severe illness presented ~2 months following a first confirmed COVID-19 episode in patients with subsequent household exposure. Genome sequencing identified several potential variations between the viruses in the separate episodes, and the cases were concluded to be reinfections. [15, 16] Both humoral and cell mediated immunity are necessary in order to elicit protective immunity against SARS-CoV-2 reinfection. Whether most infected persons mount sufficient and sustained immune memory responses, such as neutralizing antibodies and memory T cells, remain still unknown. Long-term studies evaluating persistence of SARS-CoV and MERS-CoV -specific IgG antibody responses more than one year after infection found that antibody titers were waning over time. However, the presence of antibodies does not necessarily equal protective immunity, especially if the neutralizing activity of the antibodies is not known or is known to be low or absent. [17] Specifically for SARS-CoV-2, some earlier studies reported rapid waning of antibody responses, attenuated after 90 days. However, a recent longer follow up study showed that antibody titers remain stable over four months. [18] Several different clades and subclades of SARS-CoV-2 have been described, with prevalence varying depending on the geographical location. Thousands of distinct variants of the virus, consisting of various mutations were reported, including over 400 variants in the spike protein. It is possible that immune pressure will select for novel strains that are able to evade immune responses to a previous infection. [19] It is not clear whether reinfection might be a more severe or milder event. A more severe event may occur due to antibody-dependent enhancement, or it may depend upon the virulence of the strain and its inoculum. [15, 16] Observations of more severe cases may also reflect a selection bias towards testing symptomatic cases. [20] On the other hand, even a non-sterilizing immune response could be protective against severe disease. A milder event of reinfection was described by To et al., explained by priming of the adaptive immune response during the first episode. [14] We cannot expect to be able to invest the same efforts to prove reinfections in three scenarios: a definite proof that the phenomenon exists; proof in patients, in a clinical situation; and proof for epidemiological purposes. For each of these purposes, we might need another definition. The ECDC has proposed a flow chart for assessing reinfection in previously confirmed COVID-19 cases, [4] however, the assessment includes unavailable tests, such as whole genome sequencing and phylogenetic analysis. For practical reasons, we propose here a laboratory definition for proven SARS-CoV-2 reinfection, and separately, we propose clinical and epidemiological definitions (see Table 1 for summary): A confirmed diagnosis of reinfection will require: 1. Confirmation of a true first episode -description of the viral load of the first episode is necessary (Ct values > 35 might imply possible contamination rather than true infection). Re-testing of the original specimen is indicated whenever possible. 2. Proof of a reinfection with two positive SARS-CoV-2 RT-PCR with Ct <35 (or proof of replicating virus by cell culture or detection of subgenomic RNA) at different timepoints Plus: 3. Confirmation of infection with 2 different phylogenetic strains by high throughput sequencing (HTS), corresponding to local epidemiology (proof of two distinct virus variants with any sequence variation between the two episodes) Plus: At least one, and ideally two, negative RT-PCR tests, on two different specimens collected between the first and second episodes, should be documented. For clinical practice, reinfection may be defined as clinical recurrence of symptoms compatible with COVID-19, accompanied by positive PCR (Ct<35), more than 90 days after the onset of the primary infection, supported by close contact exposure or outbreak settings, and no evidence of another cause of infection. In the presence of epidemiological risk factors (i.e, significant exposure), reinfection should be considered during the first 90 days, if clinical symptoms of the first episode resolved and two PCR tests were negative prior to the new episode. Viral culture, if collected, is expected to be positive. Serology does not play a factor in the reinfection definition and could be either positive or negative after the first infection. A negative serology indicates either the absence of potent detectable immune response or antibody waning. Positive serology indicates that neutralizing antibodies titers were not sufficient to eliminate the viral inoculum or that the infecting virus is substantially different to the first infection and is not recognized by the antibodies. For epidemiological purposes, reinfection could be defined as any positive RT-PCR test (Ct values < 35) more than 90 days from first episode, regardless of symptoms. Since confirmation by genotypic assays is time and resource consuming, any case of suspected reinfection should be considered for isolation. Regarding RT-PCR repositivity within 90 days, further studies performing genotypic assays of first-and second-episode specimens are needed in order to define reinfection during this period. COVID-19 relapse (also described in the literature as "recrudescence" or "recurrence" or "reactivation") -clinical recurrence of symptoms compatible with COVID-19, accompanied by positive/persisting RT-PCR within 90 days of primary infection, and supported by the absence of epidemiological exposure or another cause of the illness. Viral culture may be positive. Demonstration of same strain by whole genome sequencing could definitively differentiate this entity from reinfection (confirmed relapse). Hence, further research is needed in order to decide whether these cases should be considered for isolation. An inflammatory syndrome, as a result of inappropriate immune response, has been suggested as an alternative explanation by Gousseff et al. However, as the authors concluded, positive PCR for all patients and positive viral cultures for some, support viral disease. SARS-CoV-2 RT-PCR re-positivity -positive RT-PCR following negative tests in an asymptomatic patient up to 90 days from the first episode. These cases probably do not represent replicative virus and do not necessitate isolation. Low viral load is usually a feature of re-positivity. The next few months will probably reveal the extent of reinfections. Fortunately, to date, it seems that reinfection is a rare event. Further research is needed in order to provide more accurate definitions in terms of timeframes, genetic changes definitions and serological status. In addition, infection control measures should be considered for cases of reinfection and relapse. Coronavirus Update (Live) Duration of Isolation and Precautions for Adults with COVID Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2 European Centre for Disease Prevention and Control E. Reinfection with SARS-CoV-2: considerations for public health Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus Seasonal coronavirus protective immunity is short-lasting Reinfection with SARS-CoV-2 and Failure of Humoral Immunity: a case report Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound? Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR Findings from investigation and analysis of re-positive cases 2020 COVID-19 reinfection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing A Case of Early Re-infection with SARS-CoV-2 Genomic evidence for reinfection with SARS-CoV-2: a case study. The Lancet Infectious Diseases 2020 A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease The Power of Antibody-Based Surveillance Variant analysis of SARS-CoV-2 genomes What reinfections mean for COVID-19. The Lancet Infectious Diseases 2020 The authors have no conflicts of interest to report. No external funding was received.All authors contributed to the writing the manuscript and reviewed the final version.